Navigation Links
PharmaNet Development Group To Showcase Innovative Solutions and Poster Presentations at AAPS 2009
Date:10/12/2009

PRINCETON, N.J., Oct. 12 /PRNewswire/ -- PharmaNet Development Group, Inc., a leading provider of clinical development services to innovative pharmaceutical, biotechnology, generic drug and medical device companies, today announced that the Company and its subsidiaries Anapharm and Taylor Technology will be showcasing a range of innovative solutions at the 2009 AAPS Annual Meeting and Exposition.

Taylor Technology and Anapharm representatives will be discussing their offerings in method development and validation, bioanalytical mass spectrometry and immunochemistry. For more information on PharmaNet Development Group and the offering of its subsidiaries, please visit the PharmaNet booth 1739 at AAPS 2009 at the Los Angeles Convention Center, Los Angeles, California from November 8 - 11, 2009.

Attendees of the conference are invited to attend a series of poster presentations by PharmaNet employees covering a wide range of scientific topics and will include the following topics:

Tuesday, November 10, 2009

Presentations from 11:00 am to 12:00 pm, Posters available from 8:00 am to 12:00 pm

Importance of Using Physiologically-Relevant Concentrations in the Evaluation of Metabolite Back-Conversion, Presenter: Betty Stamatiou, Co-Authors: Sylvain Lachance, Ann Levesque, Robert Masse, Betty Stamatiou

A Useful Derivatization Tool to Enhance Sensitivity for the Quantitation of Phenylephrine at Low Picograms levels by LCMSMS, Presenter: Ann Levesque, Co-Authors: Serge Auger, Sylvain Lachance, Ann Levesque, Robert Masse

Relative Instability of Deuterated Internal Standard under Different pH Conditions and According to Deuterium Atoms Location, Presenter: Nathalie Pelletier, Co-Authors: Nadine Boudreau, Sylvain Lachance, Ann Levesque, Robert Masse, Nathalie Pelletier, Caroline Savard

Precautions Required to Quantify a Thermally Labile [beta]-lactone in Human Plasma by LC/MS/MS, Presenter: Stephanie Turcotte, Co-Authors: Sylvain Lachance, Ann Levesque, Robert Masse, Stephanie Turcotte

Summation of Multiple Transitions Monitoring in LC/MS/MS to Enhance Signal to Noise and to Reduce Variability, Presenter: Sylvain Lachance, Co-Authors: Philippe Belanger, Jean Couture, Sebastien Gagne, Sylvain Lachance, Ann Levesque, Isabelle Levesque, Robert Masse, François Viel

A Useful Computerized Tool for the Evaluation of Bioanalytical Methods and Study Sample Analysis Robustness, Presenter: Nadine Boudreau, Co-Authors: Patrice Arcand, Serge Auger, Philippe Belanger, Nadine Boudreau, Ann Levesque, Robert Masse

How to Avoid Metabolite Back-Conversion: Tests Performed to Prove the Absence of Back-Conversion for Clopidogrel LCMSMS Method in Human Plasma, Presenter: Guy Havard, Co-Authors: Marie-Eve Coulombe, Guy Havard, Sylvain Lachance, Ann Levesque, Robert Masse

Lipemic Effect Evaluation on Detection Variability Using Natural and Synthetic Lipemic Plasma in LC/MS/MS Method, Presenter: Sofi Gagnon-Carignan, Co-Authors: Sofi Gagnon-Carignan, Sylvain Lachance, Nancy Lampron, Ann Levesque, Robert Masse

Trouble-Shooting of Least-Expected Causes in Bioanalytical Method Development and Application, Presenter: Aimin Tan, Co-Authors: Sebastien Gagne, Robert Masse, Valerie Montminy, Adrien Musuku, Aimin Tan

Wednesday, November 11, 2009

Presentations from 11:00 am to 12:00 pm, Posters available from 8:00 am to 12:00 pm

Quantification of the Impact of Bioanalytical Method Variability on Bioequivalence Primary Pharmacokinetic Parameters, Presenter: Audrey Saint-Laurent, Co-Authors: Audrey Lainesse, Robert Masse, Audrey Saint-Laurent, Eric Shink, Mario Tanguay

Thursday, November 12, 2009

Presentations from 11:00 am to 12:00 pm, Posters available from 8:00 am to 12:00 pm

Enantiomeric Separation in Chiral Chromatography Enhanced by Propionic Anhydride as a Chemical Modifier, Presenter: Robert Masse, Co-Authors: Nicolas Jean, Sylvain Lachance, Ann Levesque, Robert Masse

For more information about PharmaNet and its subsidiaries' comprehensive range of services, please visit the PharmaNet Development Group booth 1739 at AAPS 2009. Alternatively, please email earlystage@pharmanet.com or visit www.pharmanet.com

About PharmaNet Development Group, Inc.

PharmaNet Development Group, Inc., a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug and medical device industries. The Company offers early and late stage consulting, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs. With approximately 2,300 employees and 40 facilities throughout the world, PharmaNet is a recognized leader in outsourced clinical development.

For further press information please contact Celine Callender, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA, United Kingdom. Phone +44 1477 539539, Fax +44 1477 539540, Email: pharmanet@scottpr.com

    Media Contact Information
    Name: Celine Callender/Laura Browne     Anne-Marie Hess
          Scott Partnership                 PharmaNet Development Group, Inc.
    Phone: +44 1477 539539                  (609) 951-6842
    Email: pharmanet@scottpr.com            ahess@pharmanet.com

SOURCE PharmaNet Development Group, Inc.


'/>"/>
SOURCE PharmaNet Development Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. Promising Cystic Fibrosis Compound on Track for Development
3. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
4. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
5. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
6. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
7. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
8. Quest Diagnostics Introduces ClariSure(TM) Test for Identifying Chromosome Abnormalities Associated With 85 Developmental Disorders in Children
9. WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development
10. EntreMed Raises $20 Million to Support Clinical Development Program
11. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... May 27, 2016 According to ... hypertension is driving ambulatory blood pressure monitoring system market ... and their ability to respond to different pressure rates, ... can lead to various cardiovascular disorders such as heart ... These diseases are growing in prevalence each year. WHO ...
(Date:5/27/2016)... SAN FRANCISCO , May 27, 2016 ... biotechnology company focused on developing products for Regenerative Medicine, Neurology and ... Commissiong will be presenting at two upcoming investor conferences: ... Conference Center, 730 Third Avenue, New York City ... at 3:00pm Marcum MicroCap Conference   ...
(Date:5/26/2016)... May 26, 2016 A key ... is the emergence of new treatments. Cardax, a development ... osteoarthritis treatment. The therapy is expected to fulfil large ... UK is conducting studies to develop new treatments for ... the genes involved in osteoarthritis are being investigated, and ...
Breaking Medicine Technology:
(Date:5/27/2016)... , ... May 27, 2016 , ... More than a ... it is not surprising that bariatric surgery has received increased attention in recent years, ... Of course, when it comes to weight loss, most people are familiar with the ...
(Date:5/27/2016)... ... 27, 2016 , ... With over 60 percent of acute stroke survivors being ... product to aid in the rehabilitation process has steadily increased. Ekso Bionics had been ... hemiplegia due to stroke. , Ekso Bionics has now received clearance from the U.S. ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed ... by inspiring human interest stories, courtesy of leaders in the nursing and health ... the industry, from leading advocates and associations—namely Jones & Bartlett Learning. , Jones ...
(Date:5/26/2016)... ... May 26, 2016 , ... There are many ways to cook a ... (NHDSC) suggests that Americans prefer their dogs straight off the grill. Of the 90 ... their favorite way to cook a hot dog, far outpacing other cooking methods such ...
(Date:5/26/2016)... ... 26, 2016 , ... Connor Sports, through its Connor Cares initiative, ... Tamika Catchings Legacy Tour that will commemorate the Indiana Fever legend’s hall-of-fame ... in all forms and levels of the game, Connor Sports has committed to a ...
Breaking Medicine News(10 mins):